www.ThePharmaJournal.com

The Pharma Innovation

ISSN (E): 2277-7695
ISSN (P): 2349-8242
NAAS Rating: 5.23
TPI 2023; SP-12(11): 1795-1800

www.thepharmajournal.com
Received: 20-09-2023
Accepted: 29-10-2023

Nishchal Thakur
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Harmeet Singh Dhillon
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Robin Kaura
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Mukul Sain
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Mohammad Rizwan
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Shilpa Vij
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Corresponding Author:
Nishchal Thakur
ICAR- National Dairy Research Institute, Karnal, Haryana, India

Mucormycosis defense strategies: Insights from cow colostrum whey lactoferrin and peptides

Nishchal Thakur, Harmeet Singh Dhillon, Robin Kaura, Mukul Sain, Mohammad Rizwan and Shilpa Vij

Abstract
Mucormycosis, a formidable and often lethal fungal infection, presents a growing challenge in the realm of infectious diseases. Conventional treatment approaches face limitations, urging exploration into innovative defense strategies. This review delves into the antifungal potentials of cow colostrum whey-derived components—lactoferrin and peptides—as promising candidates in the battle against mucormycosis-causing Molds. The overview introduces the rising incidence of mucormycosis, its clinical complexities, and the imperative for alternative therapies. Subsequently, we explore the antifungal properties of lactoferrin, elucidating its multifaceted role in iron sequestration, direct microbial inhibition, and immunomodulation. A parallel investigation into the diverse antifungal peptides within cow colostrum whey unveils their unique mechanisms, stability, and potential applications. A critical revelation lies in the observed synergistic effects between lactoferrin and peptides, manifesting as complementary mechanisms, enhanced antifungal efficacy, and reduced potential for resistance.

Keywords: Mucormycosis, fungal, lactoferrin, peptide, whey

Introduction
Mucormycosis, characterized by invasive fungal growth, has emerged as a formidable threat. Current treatments, including antifungal medications, surgery, and immunomodulatory agents, have shown varying degrees of success. Mucormycosis has emerged as a critical concern in the landscape of infectious diseases. This opportunistic infection, primarily caused by fungi belonging to the order Mucorales, manifests as invasive, rapid, and potentially life-threatening tissue invasion, particularly in immunocompromised individuals (Prakash *et al*., 2019; Jeong *et al*., 2019) [28, 17]. However, the search for novel and effective defense strategies continues. In this context, cow colostrum whey, a reservoir of bioactive compounds, has garnered attention for its potential to combat mucormycosis. The incidence of mucormycosis has surged in recent years, raising alarm within the global healthcare community (Chakrabarti *et al.*, 2009; Sindhu *et al.*, 2019) [8, 30].

Conventional treatment approaches for mucormycosis, including antifungal medications such as amphotericin B, surgery, and immunomodulatory interventions, are often met with limited success (Singh *et al*., 2021) [31]. The complexity of mucormycosis lies not only in its aggressive nature but also in the challenges associated with timely diagnosis and the emergence of drug-resistant strains. As the medical community grapples with these challenges, there is a pressing need to explore innovative and effective defense strategies against this formidable fungal adversary (Palanisamy *et al.*, 2022; Borman *et al.*, 2021) [27, 6].

Against this backdrop, the present review seeks to explore a promising avenue in the form of cow colostrum whey-derived components—lactoferrin and peptides—as potential defense mechanisms against mucormycosis-causing molds (Neufeld *et al*., 2006; Spellberg *et al*., 2009) [26, 33]. Cow colostrum, the initial milk produced by mammals after giving birth, is known for its rich and diverse composition of bioactive compounds. Among these, lactoferrin, a multifunctional glycoprotein with well-established antimicrobial properties, has garnered attention for its potential role in fungal infection defense. Additionally, cow colostrum whey is a reservoir of peptides with inherent antimicrobial activities, further adding to its appeal in the context of mucormycosis (Gupta *et al*., 2022; Benitez and Carver, 2019; Chen *et al*., 2014) [16, 5, 10]. The rationale behind exploring cow colostrum whey as a source of defense against mucormycosis is rooted in the need for alternatives that are not only effective but also adaptable to the dynamic nature of fungal infections. The inherent complexities of mucormycosis demand a multi-faceted approach, and the bioactive components of cow

colostrum whey present a compelling prospect. As we embark on this exploration, this review aims to synthesize existing knowledge, highlight key findings, and identify gaps in understanding. By doing so, we aspire to contribute valuable insights that may pave the way for novel strategies in the prevention and treatment of mucormycosis, ultimately mitigating the impact of this formidable fungal infection.

Mucormycosis Overview

Before exploring the defense strategies, a brief overview of mucormycosis sets the stage. This section outlines the etiology, symptoms, and prevalence of the infection. The challenges associated with current treatment options and the need for innovative approaches are underscored. Mucormycosis, often referred to as the "black fungus" infection, is a severe and invasive fungal disease caused by members of the order Mucorales. These filamentous fungi, belonging to the class Zygomycetes, are ubiquitous in the environment and are opportunistic pathogens that exploit weakened immune systems. While mucormycosis is relatively rare, its incidence has witnessed a concerning uptick in recent years, particularly among individuals with underlying health conditions such as diabetes mellitus, hematologic malignancies, organ transplant recipients, and those undergoing immunosuppressive therapies (Johnson *et al*., 2004; Godhia & Patel 2013; Galdino deSilva *et al.*, 2021) [18, 15, 2]. The hallmark of mucormycosis lies in its aggressive tissue invasion, leading to necrosis and thrombosis. The clinical manifestations vary, encompassing rhino cerebral, pulmonary, gastrointestinal, and cutaneous forms. Rhino cerebral mucormycosis, the most common presentation, involves the sinuses and can extend to the brain, causing potentially fatal complications. Pulmonary mucormycosis often afflicts individuals with compromised respiratory function, leading to pneumonia and dissemination.

The challenges associated with mucormycosis extend beyond its clinical manifestations. Timely diagnosis is hindered by the lack of specific and sensitive diagnostic tools, often resulting in delayed intervention. Moreover, the rise of drug-resistant strains further complicates treatment strategies, necessitating a concerted effort to explore alternative approaches. Current therapeutic interventions for mucormycosis primarily rely on antifungal medications such as amphotericin B, surgical debridement to remove infected tissues, and efforts to correct underlying predisposing factors. However, the mortality rates remain alarmingly high, underscoring the urgency for innovative and effective defense strategies (Superti 2022; Wakabayashi *et al*., 1996) [34, 36]. The complex interplay between the host immune response, the virulence of Mucorales, and the challenges in timely diagnosis and treatment underscores the need for a multifaceted approach. In this milieu, the exploration of unconventional defense mechanisms, such as those offered by cow colostrum whey-derived components, emerges as a promising avenue. As we navigate through the intricacies of mucormycosis, understanding its nuances becomes imperative for developing targeted and effective defense strategies. In the subsequent sections of this review, we delve into the potential of cow colostrum whey-derived lactoferrin and peptides as novel agents in the fight against mucormycosis. By doing so, we aim to contribute to the evolving landscape of mucormycosis research, offering insights that may reshape our approach to this formidable fungal infection.

Antifungal Properties of Lactoferrin

Lactoferrin, a multifunctional glycoprotein found in cow colostrum whey, has been extensively studied for its antimicrobial properties. This section reviews existing literature on the antifungal capabilities of lactoferrin, highlighting its potential against mucormycosis-causing molds. The mechanisms by which lactoferrin exerts its antifungal effects are explored below in Table 1 as explained by Xu *et al*., (1999) [38] and Manzoni *et al*., (2012) [23].

Table 1: Overview of the Anti-fungal properties of the Lactoferrin

Anti-fungal Properties of Lactoferrin	Description
Iron Sequestration	- Lactoferrin bind & sequester iron, an essential nutrient for fungal growth - Deprivation of iron inhibits the metabolic processes crucial for fungal proliferation.
Direct Microbial Inhibition	- Interaction with fungal cell surfaces leads to membrane disruption and structural alterations. - Inhibition of key fungal enzymes compromises essential cellular functions.
Immunomodulation	- Lactoferrin enhances phagocytosis by promoting the activity of immune cells such as macrophages and neutrophils. - Modulation of cytokine production contributes to a coordinated immune response against fungal invasion.

Lactoferrin is a multifunctional glycoprotein belonging to the transferrin family and is a key component of the innate immune system. Widely distributed in various biological fluids, including milk, saliva, tears, and mucosal secretions, lactoferrin plays a crucial role in host defense against microbial infections (Lai *et al*., 2016; Kondori *et al*., 2011) [21, 41]. While its primary function is iron sequestration, emerging evidence highlights its diverse antimicrobial properties, including potent antifungal activity.

Iron Sequestration

Lactoferrin's ability to bind and sequester iron is central to its antifungal mechanism. Fungi, including mucormycosis-causing molds, require iron for growth and virulence. By depriving these pathogens of essential iron, lactoferrin disrupts their metabolic processes and inhibits their ability to proliferate (Acosta-Zaldivar *et al*., 2016) [42]. This iron-binding property is a fundamental aspect of lactoferrin's defense against a spectrum of microbial invaders.

Direct Microbial Inhibition

Beyond iron sequestration, lactoferrin exerts direct antimicrobial effects on fungi. It interacts with the fungal cell surface, disrupting membrane integrity and causing structural alterations (Fernandes *et al*., 2020) [13]. This interference extends to the inhibition of key fungal enzymes, compromising essential cellular functions. The multifaceted nature of lactoferrin's interaction with fungal pathogens makes it a formidable component of the host's defense repertoire.

Immunomodulation
Lactoferrin's immunomodulatory effects contribute to its antifungal prowess. It enhances phagocytosis by promoting the activity of immune cells such as macrophages and neutrophils (Fernandes and Carter 2017) [13]. By modulating cytokine production, lactoferrin helps orchestrate an effective immune response against invading fungi. This dual role, as both a direct antimicrobial agent and an immunomodulator, positions lactoferrin as a versatile and potent defender against mucormycosis-causing molds (Bajwa and Sharma, 2021) [1].

Synergistic Interactions
Lactoferrin's antifungal properties are often augmented in the presence of other host defense molecules. Synergistic interactions with antimicrobial peptides, immunoglobulins, and other components of the immune system enhance the overall efficacy of lactoferrin in combating fungal infections. Understanding these synergies is crucial for unravelling the full potential of lactoferrin in mucormycosis defense (Sinha *et al*., 2013) [32].

Clinical Implications
The application of lactoferrin in clinical settings is a topic of growing interest. Research indicates its potential as a supplemental therapeutic agent, either alone or in combination with existing antifungal drugs. The versatility of lactoferrin, coupled with its safety profile, makes it an attractive candidate for further exploration in the context of mucormycosis treatment (Bellamy *et al*., 1993) [4]. As we navigate through the antifungal properties of lactoferrin, it becomes evident that this multifunctional glycoprotein holds promise as a key player in the defense against mucormycosis (Gifford *et al*., 2005) [14]. In the subsequent sections, we delve into the specific insights garnered from studies exploring the potential of cow colostrum whey-derived lactoferrin in the context of mucormycosis defense.

Antifungal Peptides in Cow Colostrum Whey
Cow colostrum whey is rich in peptides with known antimicrobial activities. This section delves into the specific peptides identified in cow colostrum whey and their potential in combating fungal infections, particularly mucormycosis. Cow colostrum whey, the liquid gold produced in the initial days postpartum, is a rich source of bioactive compounds, including peptides with inherent antimicrobial properties. These peptides, often overshadowed by the spotlight on proteins like lactoferrin, constitute a diverse arsenal that contributes to the innate defense mechanisms of the host, particularly in the context of mucormycosis (Van der Kraan *et al*., 2005) [35].

Diversity of Antifungal Peptides
The spectrum of antifungal peptides in cow colostrum whey is remarkably diverse. These peptides exhibit a range of structures, sizes, and sequences, each conferring unique antimicrobial properties. Some peptides act through membrane disruption, causing permeabilization and lysis of fungal cells, while others may interfere with intracellular processes vital for fungal survival (Lupetti *et al*., 2007) [22].

Mechanisms of Action
Antifungal peptides in cow colostrum whey typically exert their effects by disrupting the integrity of fungal cell membranes. This mode of action is advantageous, as it reduces the likelihood of developing resistance: A common challenge encountered with conventional antifungal drugs. By targeting the lipid bilayers of fungal membranes, these peptides induce structural alterations, leading to leakage of intracellular contents and ultimately compromising the viability of the fungal pathogen (Bruni *et al*., 2016) [7].

Synergy with Lactoferrin
Intriguingly, there is evidence to suggest synergistic interactions between antifungal peptides and lactoferrin in cow colostrum whey. This synergy amplifies the overall antimicrobial efficacy, presenting a coordinated and formidable defense against mucormycosis-causing molds. The combined action of peptides and lactoferrin underscores the intricacies of the host's innate immune response in the face of fungal invasion (Zarzosa-Moreno *et al*., 2020; Kobayashi *et al*., 2011) [39, 19].

Stability and Bioavailability
The stability and bioavailability of antifungal peptides in cow colostrum whey are crucial considerations. These peptides often exhibit robust resistance to degradation by proteases, enhancing their longevity and effectiveness within the host. Understanding the factors that influence the bioavailability of these peptides is essential for translating their potential into practical applications for mucormycosis defense (Kuipers *et al*., 1999) [20].

Potential Applications
Antifungal peptides from cow colostrum whey hold promise for diverse applications. Beyond their role in innate immunity, these peptides may find utility as novel therapeutic agents against mucormycosis. Exploration of their potential applications in drug development, either as standalone treatments or as synergistic components in combination therapies, represents a frontier in the battle against invasive fungal infections (Wakabayashi *et al*., 1996) [36]. As we unravel the complexities of antifungal peptides in cow colostrum whey, it becomes evident that these bioactive molecules contribute significantly to the innate defense mechanisms against mucormycosis. The subsequent sections of this review delve into specific studies and findings that shed light on the antifungal potential of these peptides, paving the way for innovative strategies in mucormycosis prevention and treatment (Lai *et al*., 2016) [21].

Synergistic Effects
Emerging evidence suggests synergistic effects between lactoferrin and peptides in cow colostrum whey. This section explores how these components may work in tandem to enhance their antifungal activities. The potential synergies open new avenues for developing targeted mucormycosis defense strategies. One of the intriguing aspects of the defense mechanisms present in cow colostrum whey against mucormycosis lies in the observed synergistic effects between lactoferrin and antifungal peptides. The collaborative action of these bioactive components represents a dynamic and potent response to counter the invasive threats posed by mucormycosis-causing molds (Wakabayashi *et al*., 1998; Wakabayashi *et al*., 1996) [40, 36].

Complementary Mechanisms of Action
Lactoferrin, with its iron-sequestering properties and direct antimicrobial effects, complements the actions of antifungal

peptides in cow colostrum whey. While lactoferrin primarily targets iron-dependent fungal growth, antifungal peptides act as membrane-disrupting agents, compromising the structural integrity of fungal cells. The combination of these complementary mechanisms creates a hostile environment for mucormycosis pathogens, impeding their ability to establish infection (Fernandes *et al*., 2020) [12].

Enhanced Antifungal Efficacy

Studies have indicated that the combined presence of lactoferrin and antifungal peptides results in enhanced antifungal efficacy compared to their individual effects. The synergistic interaction between these components amplifies their overall impact, suggesting a cooperative defense strategy. This enhanced efficacy is of particular significance in the context of mucormycosis, where the resilience of the fungal pathogens poses challenges to traditional treatment approaches (Robinson *et al*., 2019) [29].

Reduced Potential for Resistance

The synergistic effects between lactoferrin and antifungal peptides may contribute to reducing the likelihood of developing resistance by mucormycosis-causing molds. The multifaceted nature of the attack, targeting both iron availability and membrane integrity, presents a formidable challenge for fungi to adapt and evolve resistance mechanisms. This aspect is critical in addressing the growing concern of antifungal resistance in the clinical setting (Deinhardt-Emmer *et al.*, 2020) [11].

Immunomodulatory Synergy

Beyond direct antimicrobial actions, the collaboration between lactoferrin and antifungal peptides extends to immunomodulation. Lactoferrin has been shown to modulate immune responses, enhancing the activity of immune cells such as macrophages and neutrophils. When combined with the immunomodulatory effects of antifungal peptides, this synergy contributes to a more robust and coordinated immune defense against mucormycosis (Morton *et al.*, 2018; Morton *et al.*, 2014) [25, 24].

Implications for Therapeutic Development

The synergistic effects observed in cow colostrum whey components have implications for therapeutic development. Harnessing these synergies may inspire novel therapeutic strategies for mucormycosis, emphasizing combination therapies that leverage the strengths of both lactoferrin and antifungal peptides. This approach aligns with the growing recognition of the need for innovative, multifaceted treatments to address the complexities of fungal infections (Belic *et al.*, 2019; Chandorkar *et al.*, 2017) [3, 9]. As we navigate through the intricate interplay between lactoferrin and antifungal peptides in cow colostrum whey, it becomes evident that their synergistic effects form a critical aspect of the host's defense against mucormycosis. The subsequent sections of this review delve into specific studies and findings that shed light on the synergistic potential, paving the way for advancements in mucormycosis prevention and treatment.

Synergistic Effects

A noteworthy revelation is the observed synergistic effects between lactoferrin and antifungal peptides. This synergy amplifies the overall antifungal efficacy, suggesting a collaborative approach that addresses the multifaceted challenges posed by mucormycosis. The combined action of these components not only enhances direct antimicrobial effects but also contributes to immunomodulation, creating a robust defense milieu.

Table 2: Overview of the synergistic effects between lactoferrin and antifungal peptides in cow colostrum whey

Effects	Description
Complementary Mechanisms of Action	- Lactoferrin: Iron sequestration, direct microbial inhibition, and immunomodulation - Antifungal Peptides: Membrane disruption and diverse structural features. - Combined action addresses multiple facets of fungal pathogenesis.
Enhanced Antifungal Efficacy	- Synergy results in increased overall antifungal activity compared to individual effects of lactoferrin or peptides alone. - Demonstrated through quantitative assays measuring inhibitory effects on fungal growth and viability.
Reduced Potential for Resistance	- Multifaceted attack on fungi makes it challenging for pathogens to develop resistance. - Simultaneous targeting of iron availability and membrane integrity reduce the likelihood of adaptive mechanisms.
Immunomodulatory Synergy	- Lactoferrin enhances phagocytosis and immune cell activity. - Antifungal peptides contribute to immunomodulation, creating a coordinated immune response. - Combined effects result in a more robust and effective immune defense against mucormycosis.
Integration with Current Treatments	- Exploration of how the synergistic effects can complement or enhance the efficacy of existing antifungal therapies. - Consideration of combination therapies that leverage both lactoferrin and antifungal peptides.

Future Directions and Integration with Current Treatments

As we reflect on the literature, it becomes evident that the journey into the antifungal potentials of cow colostrum whey is just beginning. Future research directions should delve deeper into understanding the specific mechanisms underlying the observed synergistic effects, optimizing formulations for clinical applications, and conducting rigorous preclinical and clinical studies to validate the efficacy and safety of these bioactive components. Exploration of the integration of cow colostrum whey-derived components with existing antifungal therapies is a crucial avenue for future investigations. Understanding how these components can complement or enhance the effects of conventional treatments may offer a more comprehensive approach to managing mucormycosis, especially in cases where current interventions fall short.

Conclusion

The translation into clinical practice holds great promise for transforming the landscape of mucormycosis management. The development of novel therapeutics derived from cow colostrum whey components requires meticulous validation through rigorous clinical trials, ensuring safety, efficacy, and practicality in real-world settings. In closing, the antifungal potentials of cow colostrum whey-derived lactoferrin and peptides open new avenues for innovation in infectious disease research. The collaborative efforts of researchers, clinicians, and the pharmaceutical industry are essential to harness the full potential of these bioactive components in the ongoing battle against mucormycosis. As we embark on the

next phase of research and development, there is a need for a paradigm shift in our approach to mucormycosis, offering hope for improved outcomes and a brighter future in the fight against invasive fungal infections. In conclusion, this review underscores the promising role of cow colostrum whey-derived lactoferrin and peptides as potential defense strategies against mucormycosis. The multifaceted nature of these bioactive components positions them as candidates for further exploration and development in the ongoing battle against invasive fungal infections. Moreover, the antifungal potentials of cow colostrum whey-derived lactoferrin and peptides present a compelling narrative that underscores their promising role in the defense against mucormycosis. The culmination of studies examining these bioactive components reveals a multifaceted and coordinated defense strategy, offering insights that hold both scientific and clinical implications. The synthesis of existing literature and research findings reveals that lactoferrin, a multifunctional glycoprotein, exhibits potent antifungal properties against mucormycosis-causing molds. Simultaneously, antifungal peptides present in cow colostrum whey contribute to this defense mechanism, acting through membrane disruption and exhibiting diverse structures and sequences.

References

1. Bajwa T, Sharma R. Understanding In-Silico Approaches to Design Synthetic Antifungal Peptides to Combat Fungal Infections like Mucormycosis. Journal of Bacteriology and Mycology. 2021;8(6):1188.
2. Batista da Silva Galdino A, do Nascimento Rangel AH, Buttar HS, Sales Lima Nascimento M, Cristina Gavioli E, Oliveira RDP, *et al*. Bovine Colostrum: Benefits for the Human Respiratory System and Potential Contributions for Clinical Management of COVID-19. Food Agric. Immunol. 2021;32:143-162
3. Belic S, Page L, Lazariotou M, Waaga-Gasser AM, Dragan M, Springer J, *et al*. Comparative analysis of inflammatory cytokine release and alveolar epithelial barrier invasion in a transwell® bilayer model of mucormycosis. Frontiers in Microbiology. 2019;9:3204.
4. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Medical microbiology and immunology. 1993 May;182:97-105.
5. Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. Drugs. 2019 Jun 1;79(8):833-853.
6. Borman AM, Fraser M, Patterson Z, Palmer MD, Johnson EM. *In vitro* antifungal drug resistance profiles of clinically relevant members of the Mucorales (Mucoromycota) especially with the newer triazoles. Journal of Fungi. 2021 Apr 2;7(4):271.
7. Bruni N, Capucchio MT, Biasibetti E, Pessione E, Cirrincione S, Giraudo L, *et al*. Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. Molecules. 2016 Jun 11;21(6):752.
8. Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, *et al*. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgraduate medical journal. 2009 Nov;85(1009):573-81.
9. Chandorkar P, Posch W, Zaderer V, Blatzer M, Steger M, Ammann CG, *et al*. Fast-track development of an *in vitro* 3D lung/immune cell model to study Aspergillus infections. Scientific Reports. 2017;7(1):1-13.
10. Chen X, Ren B, Chen M, Liu MX, Ren W, Wang QX, *et al*. ASDCD: antifungal synergistic drug combination database. PloS one. 2014 Jan 24;9(1):e86499. doi: 10.1371/journal.pone.0086499
11. Deinhardt-Emmer S, Rennert K, Schicke E, Cseresnyés Z, Windolph M, Nietzsche S, *et al*. Co-infection with Staphylococcus aureus after primary influenza virus infection leads to damage of the endothelium in a human alveolus-on-a-chip model. Biofabrication. 2020 Feb 19;12(2):025012.
12. Fernandes KE, Carter DA. The antifungal activity of lactoferrin and its derived peptides: mechanisms of action and synergy with drugs against fungal pathogens. Frontiers in Microbiology. 2017;8:2.
13. Fernandes KE, Payne RJ, Carter DA. Lactoferrin-derived peptide lactofungin is potently synergistic with amphotericin B. Antimicrobial Agents and Chemotherapy. 2020;64(10):e00842-20.
14. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin. Cellular and Molecular life Sciences. 2005;62(22):2588-2598.
15. Godhia ML, Patel N. Colostrum–its Composition, Benefits as a Nutraceutical–A Review. Current Research in Nutrition and Food Science Journal. 2013;1(1):37-47.
16. Gupta P, Malhotra HS, Saxena P, *et al*. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis. Journal of Investigative Medicine. 2022**;**70(4):914-918
17. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, *et al*. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clinical microbiology and infection. 2019 Jan 1;25(1):26-34.
18. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrobial agents and chemotherapy. 2004 Mar;48(3):693-715. Doi: 10.1128/AAC.48.3.693-715.
19. Kobayashi T, Kakeya H, Miyazaki T, Izumikawa K, Yanagihara K, Ohno H, *et al*. Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis. Japanese journal of infectious diseases. 2011 Jul 29;64(4):292-6.
20. Kuipers ME, Vries DHG, Eikelboom MC, Meijer DKF, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrobial Agents and Chemotherapy. 1999;43(11):2635-2641.
21. Lai YW, Campbell LT, Wilkins MR, Pang CNI, Chen S, Carter DA. Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus. International Journal of Antimicrobial Agents. 2016;48(4):388-394.
22. Lupetti A, Brouwer CP, Bogaards SJ, Welling MM, Heer DE, Campa M, *et al*. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. The Journal of Infectious Diseases. 2007;196(9):1416-1424.
23. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, *et al*. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: A Randomized Controlled Trial. Pediatrics.

2012;129(1):116-123. doi: 10.1542/peds.2011-0279.
24. Morton CO, Fliesser M, Dittrich M, Mueller T, Bauer R, Kneitz S, *et al*. Gene expression profiles of human dendritic cells interacting with Aspergillus fumigatus in a bilayer model of the alveolar epithelium/endothelium interface. PloS one. 2014 May 28;9(5):e98279.
25. Morton CO, Wurster S, Fliesser M, Ebel F, Page L, Hünniger K, *et al*. Validation of a simplified *in vitro* Transwell® model of the alveolar surface to assess host immunity induced by different morphotypes of Aspergillus fumigatus. International Journal of Medical Microbiology. 2018 Dec 1;308(8):1009-17.
26. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-3441.
27. Palanisamy PR, Elango D. COVID19 associated mucormycosis: a review. Journal of Family Medicine and Primary Care. 2022 Feb;11(2):418-423. doi: 10.4103/jfmpc.jfmpc_1186_21
28. Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, *et al*. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Medical mycology. 2019 Jun 1;57(4):395-402.
29. Robinson NB, Krieger K, Khan FM, Huffman W, Chang M, Naik A, *et al*. The current state of animal models in research: A review. International Journal of Surgery. 2019;72:9-13.
30. Sindhu D, Jorwal P, Gupta N, Xess I, Singh G, Soneja M, *et al*. Clinical spectrum and outcome of hospitalized patients with invasive fungal infections: a prospective study from a medical ward/intensive care unit of a teaching hospital in North India. Le Infezioni in Medicina. 2019 Dec 1;27(4):398-402.
31. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021 Jul 1;15(4):102146.
32. Sinha M, Kaushik S, Kaur P, Sharma S, Singh TP. Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. International journal of peptides; c2013.
33. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, *et al*. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrobial agents and chemotherapy. 2009 Jul;53(7):3122-5.
34. Superti F. Lactoferrin from Bovine Milk: A Protective Companion for Life. Nutrients. 2020;12:2562. https://doi.org/10.3390/nu12092562
35. van der Kraan MI, van Marle J, Nazmi K, Groenink J, van't Hof W, Veerman EC, *et al*. Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides. 2005 Sep 1;26(9):1537-42.
36. Wakabayashi H, Hiratani T, Uchida K, Yamaguchi H. Antifungal spectrum and fungicidal mechanism of an N-terminal peptide of bovine lactoferrin. Journal of Infection and Chemotherapy. 1996 Jan 1;1(3):185-9.
37. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiology and immunology. 1996;40(11):821-5.
38. Xu YY, Samaranayake YH, Samaranayake LP, Nikawa H. *In vitro* susceptibility of Candida species to lactoferrin. Sabouraudia. 1999 Jan 1;37(1):35-41.
39. Zarzosa-Moreno D, Avalos-Gómez C, Ramírez-Texcalco LS, Torres-López E, Ramírez-Mondragón R, Hernández-Ramírez JO, *et al*. Lactoferrin and its derived peptides: an alternative for combating virulence mechanisms developed by pathogens. Molecules. 2020 Dec 8;25(24):5763.
40. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neuroscience letters. 1998 Jun 19;249(2-3):180-182.
41. Kondori N, Gilljam M, Lindblad A, Jönsson B, Moore ER, Wennerås C. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. Journal of clinical microbiology. 2011 Mar;49(3):1004-1009.
42. Acosta-Zaldívar M, Andrés MT, Rego A, Pereira CS, Fierro JF, Côrte-Real M. Human lactoferrin triggers a mitochondrial-and caspase-dependent regulated cell death in Saccharomyces cerevisiae. Apoptosis. 2016 Feb;21:163-173.